Accentia, Inc.
5310 Cypress Center Drive #101
Tampa
Florida
33609
United States
Tel: 813-864-2554
Fax: 813-287-6642
Website: http://www.accentia.net/
8 articles about Accentia, Inc.
-
Accentia, Inc., Biovest International, Inc. Emerges from Chapter 11 Reorganization
11/17/2010
-
Accentia, Inc. Files Plan of Reorganization; Restructuring Supports Plans to Advance Promising Multiple Sclerosis Therapy into Late-Stage Clinical Trial
6/1/2010
-
Accentia, Inc.'s CEO Provides Outlook for 2008 including Update on SinuNase Phase 3 Blinded Trial Results on 80% of Patients
1/7/2008
-
Accentia, Inc. Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis
10/8/2007
-
Accentia, Inc. Says Interim Data on SinuNase Promising
6/28/2007
-
FDA Gives Permission To Use Very Sensitive Molecular Evidence Of Cancer In BiovaxID Pivotal Phase 3: Company Intends To Use Blood Test To File Application For Accelerated Approval
5/16/2006
-
Accentia, Inc. Says Cancer Vaccine Raises Survival, Shares Up
1/24/2006
-
Accentia Biopharmaceuticals Licenses Targeted Technology For Treatment Of Chronic Rhinosinusitis (CRS): 37 Million Affected In The US And No Approved Pharmaceutical
4/13/2004